Show simple item record

dc.contributor.authorDíaz, Marta
dc.contributor.authorGallego-Escuredo, José M.
dc.contributor.authorLópez-Bermejo, Abel
dc.contributor.authorde Zegher, Francis
dc.contributor.authorVillarroya, Francesc
dc.contributor.authorIbáñez, Lourdes
dc.date.accessioned2020-06-17T10:56:23Z
dc.date.available2020-06-17T10:56:23Z
dc.date.issued2018
dc.identifier.issn1687-8337
dc.identifier.issn1687-8345 (Online)
dc.identifier.urihttp://hdl.handle.net/10459.1/69042
dc.description.abstractBackground: Fetuin-A is a glycoprotein produced in the liver and related to metabolic syndrome; fetuin-A secretion is divergently regulated in different pathological conditions. In girls with polycystic ovary syndrome (PCOS), insulin sensitization results in a more favorable endocrine-metabolic outcome than oral contraception; we assessed whether those differences are underscored by changes in circulating fetuin-A. Methods: Fetuin-A concentration endocrine-metabolic markers and hepatovisceral fat were measured longitudinally in 35 PCOS girls [age, 16 yr; body mass index (BMI), 23 kg/m2] randomized to receive either oral contraception [ethinylestradiol-levonorgestrel (n = 18)] or a low-dose combination of spironolactone, pioglitazone, and metformin (SPIOMET, n = 17) over 12 months. Healthy adolescent girls (age- and BMI-matched) were used as controls (n = 25). Results: Pretreatment fetuin-A serum levels in PCOS girls were lower than those in controls. After 12 months on treatment, fetuin-A raised to control levels only in the SPIOMET subgroup (P = 0.009, versus oral contraception); this increase was paralleled by a healthier metabolic profile with less hepatic fat (by MRI); baseline serum fetuin-A as well as the changes over 12 months was inversely related to hepatic adiposity. Conclusions: A low-dose combination of insulin sensitizers and an antiandrogen-but not oral contraception-normalizes fetuin-A levels in adolescent girls with PCOS. This trial is registered with ISRCTN29234515.ca_ES
dc.description.sponsorshipThis study was supported by a grant from the ISCIII and the Fondo Europeo de Desarrollo Regional (FEDER), Madrid, Spain (PI15/01078) and by MINECO (SAF2014-55725)ca_ES
dc.language.isoengca_ES
dc.publisherHindawica_ES
dc.relationMINECO/PN2013-2016/SAF2014-55725ca_ES
dc.relation.isformatofReproducció del document publicat a https://doi.org/10.1155/2018/4192940ca_ES
dc.relation.ispartofInternational Journal of Endocrinology, 2018, núm. 4192940ca_ES
dc.rightscc-by, (c) Díaz et al., 2018ca_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subject.otherSíndrome dels ovaris poliquísticsca_ES
dc.subject.otherGlicoproteïnesca_ES
dc.titleLow-Dose Spironolactone-Pioglitazone-Metformin Normalizes Circulating Fetuin-A Concentrations in Adolescent Girls with Polycystic Ovary Syndromeca_ES
dc.typeinfo:eu-repo/semantics/articleca_ES
dc.type.versioninfo:eu-repo/semantics/publishedVersionca_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccessca_ES
dc.identifier.doihttps://doi.org/10.1155/2018/4192940


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

cc-by, (c) Díaz et al., 2018
Except where otherwise noted, this item's license is described as cc-by, (c) Díaz et al., 2018